CN100455581C - 对黑皮质素受体具有亲和性的咪唑并吡啶衍生物 - Google Patents

对黑皮质素受体具有亲和性的咪唑并吡啶衍生物 Download PDF

Info

Publication number
CN100455581C
CN100455581C CNB2004800084919A CN200480008491A CN100455581C CN 100455581 C CN100455581 C CN 100455581C CN B2004800084919 A CNB2004800084919 A CN B2004800084919A CN 200480008491 A CN200480008491 A CN 200480008491A CN 100455581 C CN100455581 C CN 100455581C
Authority
CN
China
Prior art keywords
group
alkyl
compound
hydrogen atom
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800084919A
Other languages
English (en)
Chinese (zh)
Other versions
CN1768058A (zh
Inventor
L·波伊图特
V·布劳特
C·萨库尔
P·鲁贝尔
P·普拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Publication of CN1768058A publication Critical patent/CN1768058A/zh
Application granted granted Critical
Publication of CN100455581C publication Critical patent/CN100455581C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
CNB2004800084919A 2003-03-31 2004-03-29 对黑皮质素受体具有亲和性的咪唑并吡啶衍生物 Expired - Fee Related CN100455581C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR03/03924 2003-03-31
FR0303924A FR2852957B1 (fr) 2003-03-31 2003-03-31 Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament

Publications (2)

Publication Number Publication Date
CN1768058A CN1768058A (zh) 2006-05-03
CN100455581C true CN100455581C (zh) 2009-01-28

Family

ID=32947292

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800084919A Expired - Fee Related CN100455581C (zh) 2003-03-31 2004-03-29 对黑皮质素受体具有亲和性的咪唑并吡啶衍生物

Country Status (17)

Country Link
US (1) US7495009B2 (https=)
EP (1) EP1615925B1 (https=)
JP (1) JP4711948B2 (https=)
KR (1) KR101102742B1 (https=)
CN (1) CN100455581C (https=)
AT (1) ATE432280T1 (https=)
AU (1) AU2004228416B9 (https=)
BR (1) BRPI0408817A (https=)
CA (1) CA2520855C (https=)
DE (1) DE602004021247D1 (https=)
ES (1) ES2327929T3 (https=)
FR (1) FR2852957B1 (https=)
IL (1) IL170834A (https=)
MX (1) MXPA05010278A (https=)
NZ (1) NZ542763A (https=)
RU (1) RU2358974C2 (https=)
WO (1) WO2004089951A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
EP2072050A1 (en) 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Compounds with anti-emetic effect
EP2072516A1 (en) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
EP2168965A1 (en) * 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CN103168032A (zh) 2010-08-05 2013-06-19 安美基公司 抑制间变性淋巴瘤激酶的苯并咪唑和氮杂苯并咪唑化合物
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
CA2862444A1 (en) 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
JP2015515472A (ja) * 2012-04-06 2015-05-28 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害薬
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
PL2970389T3 (pl) 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
TWI696621B (zh) 2014-12-18 2020-06-21 美商健臻公司 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2019158731A1 (en) * 2018-02-16 2019-08-22 Ucb Biopharma Sprl Pharmaceutical 6,5 heterobicyclic ring derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091752A1 (en) * 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
US6350760B1 (en) * 1999-06-04 2002-02-26 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
WO2002060879A2 (en) * 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4416433A1 (de) * 1994-05-10 1995-11-16 Hoechst Ag Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
UA62972C2 (en) * 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
MXPA02001160A (es) * 1999-08-04 2002-07-02 Millennium Pharm Inc Compuestos que se unen a los receptores para melanocortina-4, y metodo de uso de estos.
AU2001236919A1 (en) 2000-02-09 2001-08-20 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Premeiotic and postmeiotic origin of teratomas: isolated teratoma stem cells for therapeutic uses
EP1465888A2 (en) * 2002-01-10 2004-10-13 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350760B1 (en) * 1999-06-04 2002-02-26 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
WO2001091752A1 (en) * 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
WO2002060879A2 (en) * 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof

Also Published As

Publication number Publication date
KR20060002893A (ko) 2006-01-09
ES2327929T3 (es) 2009-11-05
DE602004021247D1 (de) 2009-07-09
KR101102742B1 (ko) 2012-01-05
IL170834A (en) 2010-12-30
AU2004228416B8 (en) 2010-03-04
NZ542763A (en) 2007-11-30
US20060173036A1 (en) 2006-08-03
ATE432280T1 (de) 2009-06-15
WO2004089951A1 (fr) 2004-10-21
CA2520855C (fr) 2014-05-13
WO2004089951A8 (fr) 2006-01-12
HK1090640A1 (zh) 2006-12-29
RU2358974C2 (ru) 2009-06-20
AU2004228416A1 (en) 2004-10-21
EP1615925A1 (fr) 2006-01-18
RU2005133441A (ru) 2006-05-10
AU2004228416B2 (en) 2010-02-11
US7495009B2 (en) 2009-02-24
CA2520855A1 (fr) 2004-10-21
JP2006522076A (ja) 2006-09-28
AU2004228416B9 (en) 2010-03-11
MXPA05010278A (es) 2005-11-17
EP1615925B1 (fr) 2009-05-27
FR2852957A1 (fr) 2004-10-01
JP4711948B2 (ja) 2011-06-29
BRPI0408817A (pt) 2006-04-04
FR2852957B1 (fr) 2005-06-10
CN1768058A (zh) 2006-05-03

Similar Documents

Publication Publication Date Title
CN100455581C (zh) 对黑皮质素受体具有亲和性的咪唑并吡啶衍生物
JP4714673B2 (ja) 新規ベンゾイミダゾール及びイミダゾピリジン誘導体並びにこれらの医薬としての使用
EP2504333B1 (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
TWI675840B (zh) 稠合嘧啶化合物或其鹽
ES2378153T3 (es) Conpuestos y composiciones que contienen diarilamina, y su uso como moduladores de receptores c-kit
CA2682016A1 (en) Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase
BR112018003812B1 (pt) Compostos de heteroarila como inibidores de irak, seu uso, composição farmacêutica, e kit
TWI631117B (zh) 吲哚啉－２－酮衍生物
BRPI0712816A2 (pt) compostos de pirrolpirimidina e seus usos
HK1223100A1 (zh) 杂环化合物
JP6305510B2 (ja) ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾロピリドン
JP2010524962A (ja) オーロラキナーゼ阻害剤のための創薬法
JP6839184B2 (ja) インドリン−２−オン誘導体
TW201726655A (zh) 吲哚咻－２－酮衍生物
MX2008001019A (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxam ida, su preparacion y su aplicacion en terapeutica.
JP2010508344A (ja) ８−スルホニル−１，３，４，８−テトラヒドロ−２ｈ−［１，４］オキサゼピノ［６，７−ｅ］インドール誘導体、および５−ｈｔ６受容体リガンドとしてのその使用
TW202404591A (zh) 作為pi3k抑制劑之苯并嘧啶-4(3h)-酮
JP2017537982A (ja) インドール及びアザインドール誘導体、並びに神経変性疾患におけるそれらの使用
WO2004080411A2 (en) Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
KR102629506B1 (ko) 피페라진-퀴놀린 유도체로서 2-에틸-5-(4-메틸-피페라진-1-일)-1-(나프탈렌-2-설포닐)-2,3-디하이드로-1h-퀴놀린-4-온의 제조방법
RU2827867C1 (ru) Пиримидин- и азотсодержащее бициклическое соединение
HK1090640B (en) Imidazopyridine derivatives as melanocortin receptor agonists
TW202604514A (zh) 作為pi3k 抑制劑之含稠合三環之化合物
RU2540074C2 (ru) Производные имидазопиразина или имидазодиазепина, активные в отношении рецептора св2
HK1257170B (en) Indolin-2-one derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1090640

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1090640

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090128

Termination date: 20150329

EXPY Termination of patent right or utility model